-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Fourth Pharmaceutical Ranks Among the Top 50 Chinese Companies in Chemical Drug R&D Strength.
Category:
Time：2022-12-10
On December 9, the 2022 High-Quality Development Conference for the Greater Health Industry and the 7th China Pharmaceutical R&D & Innovation Summit, co-organized by Yaozhi.com and China Pharmaceutical Journal, opened in Chongqing. During the conference, six major rankings of China’s pharmaceutical R&D strength for 2022 were officially released. Shijiazhuang Fourth Pharmaceutical Co., Ltd. was honored to be listed on both the “Top 100 Chinese Pharmaceutical R&D Comprehensive Strength Ranking 2022” and the “Top 100 Chinese Chemical Pharmaceutical R&D Strength Ranking 2022,” placing 52nd and 40th on these respective lists.
On December 9, the 2022 High-Quality Development Conference for the Greater Health Industry and the 7th China Pharmaceutical R&D & Innovation Summit, co-organized by Yaozhi.com and China Pharmaceutical Journal, opened in Chongqing. During the conference, six major rankings of China’s pharmaceutical R&D strength for 2022 were officially released. Shijiazhuang Fourth Pharmaceutical Co., Ltd. was honored to be listed on both the “Top 100 Chinese Pharmaceutical R&D Comprehensive Strength Rankings 2022” and the “Top 100 Chinese Chemical Pharmaceutical R&D Strength Rankings 2022,” ranking 52nd and 40th respectively on these lists.
The “2022 China Pharmaceutical R&D Strength Ranking” series of lists was compiled through a comprehensive statistical analysis of various R&D-related data—including the number of drug applications approved in 2021, the amount of R&D investment by pharmaceutical companies, clinical trials of drugs, patent filings, and historical rankings of pharmaceutical R&D—conducted by Yaozhi.com, the Expert Committee for the Pharmaceutical R&D Strength Ranking, and the Organizing Committee of the 2022 China Pharmaceutical R&D Innovation Summit. This ranking excludes the impact of market and sales strategies on the companies’ performance.
In recent years, Shijiazhuang No.4 Pharmaceutical has been driven by innovation, boldly tackling key “bottleneck” technologies. The company has strategically positioned itself in fields such as antiviral, antibacterial, anti-tumor, nervous system, cardiovascular, digestive, and anesthetic therapies, and is comprehensively promoting the development and research of generic drugs, innovative drugs, specialty active pharmaceutical ingredients, pharmaceutical packaging materials, and products undergoing consistency evaluations. Particularly over the past two years, benefiting from a comprehensive package of supportive policies at the national, provincial, and municipal levels, the company has continuously increased its R&D investment. Leveraging high-level innovation platforms—including the enterprise technology center recognized by five national agencies and the National-Local Joint Engineering Laboratory—it has joined forces with numerous renowned universities and research institutes, such as China Pharmaceutical University, Zhengzhou University, Shenyang Pharmaceutical University, and the Chinese Academy of Medical Sciences. By bringing together leading pharmaceutical experts and academic pioneers from both home and abroad, the company has established an innovation consortium led by the enterprise, supported by universities and research institutions, and characterized by synergistic collaboration among all relevant innovation players. This collaborative ecosystem continually builds new competitive advantages, shapes new industry patterns, and creates fresh opportunities for the sector’s dynamic advancement.
Continuous innovation has enabled Shijiazhuang Fourth Pharmaceutical to accumulate a wealth of R&D achievements that are now yielding remarkable results. Currently, the company has nearly 200 projects under development, among which three first-class new drugs—targeting liver fibrosis and pulmonary arterial hypertension, among other conditions—have either been approved for clinical trials or have already been submitted for clinical trial applications. Over 100 additional new products are awaiting approval. Since the beginning of this year, the company has obtained a total of 36 product approvals, including 27 formulation approvals. The company ranks among the industry leaders in both the efficiency of developing specialty generic drugs and the number of applications submitted. To date, it has filed a cumulative total of 347 patent applications, including 192 invention patents and 16 international invention patent applications. In the past three years, the growth rate of its invention patent applications has reached 327%. This relentless commitment to innovation has provided the company with a stronger foundation and a powerful engine for high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license